The first full industry chain product of Xubidi Pharmaceutical (m-Phlorophenol Injection, m-Phlorophenol API, m-Phlorophenol Trimethyl Ether API) has been approved for listing, ushering in a new stage of company development! Since its establishment, the company has successfully applied for approval cases and achieved a business transformation from CRO to self-developed, self-produced, and self sold.
Relying on a product research and development team, production quality team, and marketing team that have been trained for a long time and are rooted in implementation, Xubidi Pharmaceutical insists on doing a good job in "small new special" barrier generic drugs, compatible with the development and innovation of long-acting complex injections, and strives to become a key player in the field of segmented treatment!
From now on, the R&D driven Xubidi Pharmaceutical will aim to declare 15 or more APIs and 20 or more formulations annually, with a progressive grading system and solid development
